(Q43039402)

12 November 2017

A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques (English)

1 reference

12 November 2017

1 reference

11

1 reference

12 November 2017

12

1 reference

12 November 2017

David Klatzmann

15

0 references

author name string

Pierre Garrone

1

1 reference

12 November 2017

Anne-Catherine Fluckiger

2

1 reference

12 November 2017

Philippe E Mangeot

3

1 reference

12 November 2017

Emmanuel Gauthier

4

1 reference

12 November 2017

Pia Dupeyrot-Lacas

5

1 reference

12 November 2017

Jimmy Mancip

6

1 reference

12 November 2017

Arnaud Cangialosi

7

1 reference

12 November 2017

Isaure Du Chéné

8

1 reference

12 November 2017

Roger LeGrand

9

1 reference

12 November 2017

Isabelle Mangeot

10

1 reference

12 November 2017

François-Loic Cosset

13

1 reference

12 November 2017

Frederic Tangy

14

1 reference

12 November 2017

Charlotte Dalba

16

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 August 2011

1 reference

Science Translational Medicine

12 November 2017

1 reference

12 November 2017

3

1 reference

12 November 2017

94

1 reference

12 November 2017

94ra71

1 reference

The role of antibodies in HIV vaccines

12 November 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Development of hepatitis C virus vaccines: challenges and progress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Virus-like particles as a vaccine delivery system: myths and facts

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Virus-like particles-universal molecular toolboxes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Characterization of functional hepatitis C virus envelope glycoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Intracellular versus cell surface assembly of retroviral pseudotypes is determined by the cellular localization of the viral glycoprotein, its capacity to interact with Gag, and the expression of the Nef protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Characterization of hepatitis C virus pseudoparticles by cryo-transmission electron microscopy using functionalized magnetic nanobeads

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Nomenclature and numbering of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Hepatitis C databases, principles and utility to researchers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Complete replication of hepatitis C virus in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Robust hepatitis C virus infection in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Neutralizing antibody response during acute and chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Is developing an HIV-1 vaccine possible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

HIV vaccines: lessons learned and the way forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Enveloped particles in the serum of chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Functional role of type I and type II interferons in antiviral defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

Detection of neutralizing antibodies with HCV pseudoparticles (HCVpp).

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3002330

10.1126/SCITRANSLMED.3002330

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference